Institutional members access full text with Ovid®

Share this article on:

Safety of influenza vaccines

Kelso, John M.

Current Opinion in Allergy and Clinical Immunology: August 2012 - Volume 12 - Issue 4 - p 383–388
doi: 10.1097/ACI.0b013e328354395d
ANAPHYLAXIS AND INSECT ALLERGY: Edited by Theodore Freeman and Ralf G. Heine

Purpose of review To review recent publications on the safety of influenza vaccines [both the injectable, inactivated trivalent influenza vaccine (TIV) and the intranasal, live attenuated influenza vaccine (LAIV)] and new recommendations regarding their use.

Recent findings Numerous studies have demonstrated that TIV can be safely administered to patients with egg allergy. Influenza vaccines are very unlikely to cause or exacerbate Guillain-Barré syndrome (GBS). TIV cannot cause asthma exacerbations, whereas there may be some slight risk that LAIV could do so. TIV is well tolerated by patients with immunocompromise. Some brands of influenza vaccine are not indicated for certain age groups due to lack of effectiveness or possible side effects.

Summary TIV should be administered to patients with egg allergy with appropriate precautions. Influenza vaccines should be withheld from patients with a history of GBS only if the GBS began within 6 weeks of prior influenza immunization. TIV should be given to patients with asthma, but they should not receive LAIV. TIV should be given to immunocompromised patients, but they should not receive LAIV. Contacts of most immunocompromised patients can receive either TIV or LAIV. Age appropriate brands of influenza vaccine should be used.

Division of Allergy, Asthma and Immunology, Scripps Clinic, San Diego, California, USA

Correspondence to John M. Kelso, MD, Division of Allergy, Asthma and Immunology, Scripps Clinic, 3811 Valley Centre Drive, San Diego, CA 92130, USA. Tel: +1 858 764 9010; fax: +1 858 764 9011; e-mail: kelso.john@scrippshealth.org

Copyright © 2012 Wolters Kluwer Health, Inc. All rights reserved.